Stock Track | Teva Pharmaceutical Plummets 5% on Disappointing 2025 Earnings Guidance Despite Solid Q4 Results

Stock Track

01-31

Teva Pharmaceutical Industries Ltd (TEVA) stock plunged over 5% in Thursday's intraday trading session, following the company's mixed fourth quarter 2024 earnings release and guidance for 2025 that fell short of analyst estimates.

The Israeli pharmaceutical giant reported revenues of $16.54 billion for the full year 2024, up 4% from the prior year and slightly exceeding expectations. Adjusted earnings per share for 2024 came in at $2.49, within the guided range of $2.40-$2.50.

However, Teva's adjusted earnings guidance for 2025 in the range of $2.35-$2.65 per share fell below the consensus analyst estimate of $2.76, disappointing investors and triggering the sell-off in the stock.

The company cited expected pricing pressure and generic competition, particularly for its key multiple sclerosis drug Copaxone, as factors weighing on its 2025 earnings outlook. Sales of Copaxone are anticipated to fall to around $370 million in 2025, down from $504 million in 2024.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1132211434"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132211434\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1132211434?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-31 02:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132211434","market":"hk","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Plummets 5% on Disappointing 2025 Earnings Guidance Despite Solid Q4 Results","media":"Stock Track","content":"<html><body><p>Teva Pharmaceutical Industries Ltd (TEVA) stock plunged over 5% in Thursday's intraday trading session, following the company's mixed fourth quarter 2024 earnings release and guidance for 2025 that fell short of analyst estimates.</p>\n<p>The Israeli pharmaceutical giant reported revenues of $16.54 billion for the full year 2024, up 4% from the prior year and slightly exceeding expectations. Adjusted earnings per share for 2024 came in at $2.49, within the guided range of $2.40-$2.50.</p>\n<p>However, Teva's adjusted earnings guidance for 2025 in the range of $2.35-$2.65 per share fell below the consensus analyst estimate of $2.76, disappointing investors and triggering the sell-off in the stock.</p>\n<p>The company cited expected pricing pressure and generic competition, particularly for its key multiple sclerosis drug Copaxone, as factors weighing on its 2025 earnings outlook. Sales of Copaxone are anticipated to fall to around $370 million in 2025, down from $504 million in 2024.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Teva Pharmaceutical Plummets 5% on Disappointing 2025 Earnings Guidance Despite Solid Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Plummets 5% on Disappointing 2025 Earnings Guidance Despite Solid Q4 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-01-31 02:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Teva Pharmaceutical Industries Ltd (TEVA) stock plunged over 5% in Thursday's intraday trading session, following the company's mixed fourth quarter 2024 earnings release and guidance for 2025 that fell short of analyst estimates.</p>\n<p>The Israeli pharmaceutical giant reported revenues of $16.54 billion for the full year 2024, up 4% from the prior year and slightly exceeding expectations. Adjusted earnings per share for 2024 came in at $2.49, within the guided range of $2.40-$2.50.</p>\n<p>However, Teva's adjusted earnings guidance for 2025 in the range of $2.35-$2.65 per share fell below the consensus analyst estimate of $2.76, disappointing investors and triggering the sell-off in the stock.</p>\n<p>The company cited expected pricing pressure and generic competition, particularly for its key multiple sclerosis drug Copaxone, as factors weighing on its 2025 earnings outlook. Sales of Copaxone are anticipated to fall to around $370 million in 2025, down from $504 million in 2024.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦製藥","start_time":0,"source_url":"","article_id":"1132211434","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132211434","pubTimestamp":1738261963,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical Industries Ltd  stock plunged over 5% in Thursday's intraday trading session, following the company's mixed fourth quarter 2024 earnings release and guidance for 2025 that fell short of analyst estimates.The Israeli pharmaceutical giant reported revenues of $16.54 billion for the full year 2024, up 4% from the prior year and slightly exceeding expectations. Adjusted earnings per share for 2024 came in at $2.49, within the guided range of $2.40-$2.50.However, Teva's adjusted e","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"尽管第四季度业绩稳健，但Teva Pharmaceutical因2025年盈利指引令人失望而暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries Ltd (TEVA) stock plunged over 5% in Thursday's intraday trading session, following the company's mixed fourth quarter 2024 earnings release and guidance for 2025 that fell short of analyst estimates.\nThe Israeli pharmaceutical giant reported revenues of $16.54 billion for the full year 2024, up 4% from the prior year and slightly exceeding expectations. Adjusted earnings per share for 2024 came in at $2.49, within the guided range of $2.40-$2.50.\nHowever, Teva's adjusted earnings guidance for 2025 in the range of $2.35-$2.65 per share fell below the consensus analyst estimate of $2.76, disappointing investors and triggering the sell-off in the stock.\nThe company cited expected pricing pressure and generic competition, particularly for its key multiple sclerosis drug Copaxone, as factors weighing on its 2025 earnings outlook. Sales of Copaxone are anticipated to fall to around $370 million in 2025, down from $504 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}